

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
THIRD QUARTER
2003

NET PRODUCT SALES DETAIL

PRODUCT	3Q `03 vs. 3Q `02					
	TOTAL % CHG	TOTAL \$	U.S. % CHG	U.S. \$	Foreign % CHG	Foreign \$
AGGRASTAT	-3%	26	-43%	7	34%	18
ARCOXIA	*	19	-	-	*	19
CANCIDAS	*	77	*	48	*	29
COZAAR / HYZAAR	13%	622	3%	229	21%	393
CRIVAN/STOCRIN	-2%	64	-20%	15	6%	49
EMEND	*	4	*	4	*	0
FOSAMAX	52%	687	55%	411	48%	276
INVANZ	*	11	*	9	*	3
MAXALT	32%	101	31%	75	38%	27
PRIMAXIN	15%	171	32%	58	7%	112
PRINIVIL / PRINZIDE	-65%	26	-76%	13	-25%	12
PROPECIA	10%	59	9%	27	11%	32
PROSCAR	-18%	126	-45%	47	16%	80
SINGULAIR	80%	616	98%	473	39%	143
TIMOPTIC/TIMOPTIC XE	-6%	39	18%	5	-8%	34
TRUSOPT/COSOPT	13%	120	13%	50	13%	70
VASOTEC / VASERETIC	-1%	186	64%	(2)	-3%	188
VIOXX	-32%	510	-52%	258	21%	252
ZOCOR	-2%	1,405	15%	994	-29%	411
HEPATITIS VACCINES	6%	71	16%	62	-34%	9
VIRAL VACCINES	11%	160	8%	149	87%	10
OTHER VACCINES	5%	81	-1%	66	46%	15

* > 100%
N/M - Not Meaningful

TOTAL SALES: VOLUME, PRICE, EXCHANGE

	3Q `03	% CHG.	VOL	PX	FX
TOTAL PHARMACEUTICAL SALES	<u>5,762</u>	<u>6%</u>	<u>3</u>	<u>1</u>	<u>2</u>
U.S.	3,514	7%	5	2	0
Foreign	2,248	6%	1	-1	6

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
NINE MONTHS YEAR TO DATE
2003

NET PRODUCT SALES DETAIL

PRODUCT	SEPTEMBER YTD '03 vs. SEPTEMBER YTD '02					
	TOTAL % CHG	TOTAL \$	U.S. % CHG	U.S. \$	Foreign % CHG	Foreign \$
AGGRASTAT	-5%	74	-52%	17	33%	58
ARCOXIA	*	46	-	-	*	46
CANCIDAS	*	185	*	110	*	75
COZAAR / HYZAAR	20%	1,796	6%	662	30%	1,133
CRIVIVAN/STOCRIN	6%	229	3%	78	7%	151
EMEND	*	19	*	19	*	0
FOSAMAX	31%	2,026	16%	1,239	63%	788
INVANZ	*	26	*	20	*	5
MAXALT	15%	230	8%	159	35%	71
PRIMAXIN	17%	480	32%	153	11%	327
PRINIVIL / PRINZIDE	-78%	100	-86%	57	-17%	43
PROPECIA	14%	175	17%	84	12%	91
PROSCAR	14%	438	7%	196	20%	242
SINGULAIR	53%	1,502	55%	1,071	48%	431
TIMOPTIC/TIMOPTIC XE	-6%	117	-37%	12	0%	105
TRUSOPT/COSOPT	13%	348	9%	145	17%	202
VASOTEC / VASERETIC	-4%	554	*	(10)	-2%	565
VIOXX	-14%	1,818	-28%	1,099	22%	719
ZOCOR	2%	3,798	12%	2,381	-12%	1,416
HEPATITIS VACCINES	10%	188	10%	159	13%	29
VIRAL VACCINES	-4%	411	-7%	383	*	28
OTHER VACCINES	14%	189	10%	151	32%	38

* > 100%
N/M - Not Meaningful

TOTAL SALES: VOLUME, PRICE, EXCHANGE

	YTD '03	% CHG.	VOL	PX	FX
TOTAL PHARMACEUTICAL SALES	<u>16,859</u>	<u>10%</u>	<u>5</u>	<u>1</u>	<u>4</u>
U.S.	10,170	7%	4	3	0
Foreign	6,689	14%	5	-1	10

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
THIRD QUARTER
2003

OTHER (INCOME)/EXPENSE, NET

	3Q `03	3Q `02	YTD 2003	YTD 2002
INTEREST INCOME	\$ (66.9)	\$ (106.5)	\$ (236.5)	\$ (307.8)
INTEREST EXPENSE	81.1	99.9	270.9	292.5
EXCHANGE (GAINS)/LOSSES	(1.7)	8.3	(25.1)	10.9
MINORITY INTERESTS	39.1	59.1	131.5	169.7
AMORTIZATION OF INTANGIBLES	36.1	29.9	104.3	89.8
Other, net	(38.9)	(43.9)	(270.2)	(123.1)
TOTAL	\$ 48.8	\$ 46.8	\$ (25.1)	\$ 132.0

JOINT VENTURE SALES DETAIL

All sales reported here are end-market JV sales, presented on a "NET" basis.

Merial	3Q `03	3Q `02	YTD 2003	YTD 2002
IVOMEK, HEARTGARD, other avermectins	\$ 141	\$ 129	\$ 352	\$ 349
FRONTLINE	183	147	485	409
Biologicals	106	91	306	274
Other Animal Health	55	43	152	135
Poultry Genetics	38	38	113	117
TOTAL MERIAL SALES	\$ 523	\$ 448	\$ 1,408	\$ 1,284

Aventis Pasteur-MSD	3Q `03	3Q `02	YTD 2003	YTD 2002
HEPATITIS VACCINES	\$ 18	\$ 19	\$ 55	\$ 49
VIRAL VACCINES	16	10	40	26
Other Vaccines	200	177	404	327
TOTAL AP-MSD SALES	\$ 234	\$ 206	\$ 499	\$ 402

Merck / Schering-Plough Collaboration	3Q `03	3Q `02	YTD 2003	YTD 2002
Zetia (Worldwide)	\$ 136	\$ -	\$ 305	\$ -
TOTAL	\$ 136	\$ -	\$ 305	\$ -